The Latest Data on Zanidatamab for HER2-Positive Biliary Tract Cancer With Shubham Pant, MD, MBBS
Expert Perspectives · Keira Smith · 2024-07-11
At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Shubham Pant, MD, MBBS, a Professor in the Department of Gastrointestinal (GI) Medical Oncology at The University of Texas MD Anderson Cancer Center, presented an abstract entitled, “Zanidatamab in Previously-Treated HER2-Positive Biliary Tract Cancer: Overall Survival (OS) and Longer Follow-Up From the Phase 2b HERIZON-BTC-01 Study.” Following his presentation, he sat down to delve further into this updated data on zanidatamab for HER2-positive biliary tract cancer, including:
- An overview of the HERIZON-BTC-01 trial and what it investigated
- The need for new treatment options for this population of patients
- The updated results he presented at ASCO
- New insights about zanidatamab discovered since the prior results presented at ASCO 2023
- Next steps and more!
About Dr. Pant
Shubham Pant, MD, MBBS, is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics in the Phase 1 Center at The University of Texas MD Anderson Cancer Center. Dr. Pant’s research focuses on GI cancers such as pancreatic and biliary cancers, with an emphasis on phase 1 trials. Dr. Pant is recognized internationally for his participation and research in clinical trials for GI cancers.